Loestrin 24 Fe Antitrust Litigation

Are you a Third Party Payor which between September 1, 2009 through and until May 2, 2019 purchased, paid, and/or provided reimbursement for some or all of the purchase price of Loestrin 24 Fe, Minastrin 24 Fe, and/or their generic equivalents?

Third Party Payors, including self insured health plans, may be entitled to compensation as a result of this litigation.

Settlement Total
$63,500,000
Settlement Total
Eligible Purchase Dates
1/20/09 - through 2/20/19
Eligible Purchase Dates
Deadline

0

days
Deadline

Background Information

The lawsuit is about the price of Loestrin 24 Fe and Minastrin 24 Fe and whether the manufacturer of these drugs and generic manufacturers  impaired or delayed the availability of allegedly less expensive generic versions. End-Payor Plaintiffs claim that class members were injured as a result of the challenged conduct by paying more for Loestrin 24 Fe, Minastrin 24 Fe, and their generic equivalents. Defendants deny all these allegations. End-Payor Plaintiffs have agreed to Settlements totaling $63,500,000 with the Defendants. The total settlement figure is comprised of settlements with two Defendants. 

The first settlement with the Lupin Defendants (the “Lupin Settlement”), has resulted in a $1,000,000.00 settlement. After allocation to claimants of 30.03% of the costs, fees, and expenses incurred in connection with the Lupin Settlement and the litigation, there will not be sufficient funds to facilitate a claims process and distribution regarding this settlement. As a result, no claim can be accepted for pharmaceutical purchases/payments/reimbursements related to the Lupin Settlement and any residual funds may be dispersed to a charity approved by the Court.

The second settlement with the Warner Chilcott Defendants (the “Warner Chilcott Settlement”) has resulted in a $62,500,000 settlement. This settlement includes only a Third Party Payor Class ("TPP Class"), and you are generally included in the TPP Class if you are a TPP (such as a self-insured health plan) that purchased, paid, and/or provided reimbursement for some or all of the purchase price for Loestrin 24 Fe, Minastrin 24 Fe, and/or generic versions of these drugs, for consumption by your members, employees, insureds, participants, or beneficiaries, other than for resale, in the United States and its territories, from September 1, 2009 through and until September 17, 2019.

Settlement Information


Filing Deadline: September 21, 2020


Settlements+

The first settlement with the Lupin Defendants, including Lupin Ltd. and Lupin Pharmaceuticals, Inc. (the “Lupin Settlement”), has resulted in a $1,000,000.00 settlement. After allocation to claimants of 30.03% of the costs, fees, and expenses incurred in connection with the Lupin Settlement and the litigation, there will not be sufficient funds to facilitate a claims process and distribution regarding this settlement. Consequently, no Claim Form is included or can be accepted for pharmaceuticals related to the Lupin Settlement and any residual funds may be dispersed to a charity approved by the Court.

The second settlement with the Warner Chilcott Defendants, including: Defendants Warner Chilcott Co., LLC f/k/a Warner Chilcott Co., Inc., Warner Chilcott (US), LLC, Warner Chilcott Sales (US), LLC, and Watson Laboratories, Inc.; related Warner Chilcott and Watson entities Warner Chilcott plc n/k/a Allergan WC Ireland Holdings Ltd., Warner Chilcott Holdings Co. III, Ltd., Warner Chilcott Corp., Warner Chilcott Laboratories Ireland Limited, Warner Chilcott Limited, and Watson Pharmaceuticals, Inc.; and parent entity Allergan plc1 (the “Warner Chilcott Settlement”) with The Warner Chilcott Settlement has resulted in a $62,500,000 settlement. This settlement includes only a Third Party Payor Class ("TPP Class"), and you are generally included in the TPP Class if you are a TPP (such as a self-insured health plan) that purchased, paid, and/or provided reimbursement for some or all of the purchase price for Loestrin 24 Fe, Minastrin 24 Fe, and/or generic versions of these drugs, for consumption by your members, employees, insureds, participants, or beneficiaries, other than for resale, in the United States and its territories, from September 1, 2009 through and until September 17, 2019.

Disclaimer

Claim forms are available from the Class Administrator. Class members are not required to sign up with any third-party service in order to participate in the monetary relief, but may instead file their claim directly with the Class Administrator. No-cost assistance will be available from the Class Administrator and Class Counsel during the claims-filing period. For additional information class members may visit www.inreloestrin24feantitrustlitigation.com, the court approved website for this case.

 

Receive More Information

Receive more information on this case by completing the form below.